Results 181 to 190 of about 8,073 (209)
Some of the next articles are maybe not open access.
The Hemodynamics of Phosphodiesterase-PDE5 Inhibitors
2004Sildenafil citrate (Viagra™; Pfizer, Inc., New York, NY) is the first of a series of orally active phosphodiesterase (PDE) type-5 inhibitors that have and will continue to transform the treatment of erectile dysfunction (ED) (1). Initially advocated as a potential alternative to oral nitrates for the treatment of stable angina pectoris, sildenafil’s ...
openaire +1 more source
Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension
Expert Review of Cardiovascular Therapy, 2006Pulmonary hypertension is a devastating disorder, characterized by vascular proliferation, intimal hypertrophy and vasoconstriction. In this disorder, alterations in the nitric oxide pathway have borne out to be important in not only vascular proliferation, but also in the maintenance of vascular tone. After synthesis by soluble guanylate cyclase, cGMP
Anna R, Hemnes, Hunter C, Champion
openaire +2 more sources
PDE5 inhibitors: are there differences?
The Canadian journal of urology, 2006The introduction of oral agents for the treatment of erectile dysfunction (ED) has revolutionized the treatment of men with erection problems of all severities and etiologies. Sildenafil, available on the world market since 1998 was joined in 2003 by tadalafil and vardenafil as effective save and reliable oral agents.
openaire +1 more source
Daily Use of PDE5-Inhibitors: The Road to Happiness?
European Urology, 2008The use of phosphodiesterase type 5 inhibitors (PDE5-I) on demand has been established as the gold standard in the treatment of erectile dysfunction (ED), with reported success rates of up to 70%. However, a considerable number of patients suffering from ED do not respond to on-demand treatment with PDE5-I. Therefore, research has focused on strategies
openaire +2 more sources
The Utility of PDE5 Inhibitors After Radical Prostatectomy
2009Radical prostatectomy of any form (open, laparoscopic, or robotic) has become a widely performed procedure for patients with clinically localized prostate cancer. This procedure may be associated with treatment-specific sequelae affecting health-related quality of life, with urinary incontinence and erectile dysfunction being the most prevalent.
SALONIA , ANDREA +3 more
openaire +2 more sources
Cardiovascular safety of PDE5 inhibitors.
The Canadian journal of urology, 2003Erectile dysfunction (ED) and cardiovascular disease share many of the same risk factors and have some common elements of pathophysiology. Clinically, they often coexist. Another link between the two conditions is that sildenafil, the first oral therapeutic agent effective in treating ED, has been shown to potentiate the hypotensive effects of nitrates,
openaire +1 more source
Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors
Biomedicine and Pharmacotherapy, 2021Wesam S Ahmed +2 more
exaly
Structure -activity relationships of PDE5 inhibitors.
Current medicinal chemistry, 2008cGMP has a short-term effect on smooth muscle tone and a longer-term effect on responses to chronic drug treatment or proliferative signals. cGMP-Phosphodiesterase type 5 (PDE5) hydrolizes cGMP, and the result is smooth muscle contraction. PDE5 is a relatively novel therapeutic target of various diseases, such as erectile dysfunction and pulmonary ...
D, Eros +6 more
openaire +1 more source
Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer’s disease
Bioorganic and Medicinal Chemistry Letters, 2020Xian-Feng Huang +2 more
exaly